The Case for More Aggressive Masking in Psychedelic Trials.

UMBRAA (unidentifiable multidrug blinding with reduced, authorized awareness) is proposed as a strategy to address masking challenges in psychedelic trials.

• Why it matters: Masking is a key problem in psychedelic studies because participants may guess their assignment, threatening the validity of trial outcomes.
• What they did: The Viewpoint outlines the UMBRAA approach, using unidentifiable multidrug blinding while allowing reduced, authorized awareness to improve blinding.
• The result: The proposal suggests UMBRAA could enable more reliable psychedelic trial designs by strengthening blinding despite the masking problem.

AI summary of the abstract · may contain errors · not medical advice · read the paper.